← back to search

Austin R. Dosch

University of Miami · US
Area of research
Oncology · Biotechnology
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Cancer Research and Treatments, Pomegranate: compositions and health benefits, and Cancer Immunotherapy and Biomarkers.
h-index
15
citations
999
works
125
NIH funding
primary concept
Medicine
email

Recent publications

Nonoperative Management of Rectal Cancer: Is “Near-Complete” Response Safe to Surveil?
Annals of Surgical Oncology 2025cited by 7position: middledoi
CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Alcoholic Pancreatitis
Cellular and Molecular Gastroenterology and Hepatology 2025cited by 6position: middledoi
Tumor Cell–Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer
Cancer Research 2024cited by 37position: middledoi
Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer
Cancer Discovery 2023cited by 126position: middledoi
Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Cancer Research Communications 2023cited by 23position: middledoi
Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer
Gastroenterology 2022cited by 158position: middledoi
Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer
Oncogene 2022cited by 45position: middledoi
Urolithin A attenuates severity of chronic pancreatitis associated with continued alcohol intake by inhibiting PI3K/AKT/mTOR signaling
American Journal of Physiology-Gastrointestinal and Liver Physiology 2022cited by 24position: middledoi
Targeting Tumor–Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer
Molecular Cancer Therapeutics 2021cited by 54position: firstdoi
Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma
Molecular Cancer Therapeutics 2021cited by 46position: middledoi
Interleukin-1 signaling in solid organ malignancies
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2021cited by 10position: firstdoi
Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer
Molecular Cancer Research 2020cited by 49position: firstdoi
Stroma secreted IL6 selects for “stem-like” population and alters pancreatic tumor microenvironment by reprogramming metabolic pathways
Cell Death and Disease 2020cited by 43position: middledoi
Minimally Invasive Surgery is Associated with an Increased Risk of Postoperative Venous Thromboembolism After Distal Pancreatectomy
Annals of Surgical Oncology 2020cited by 12position: middledoi
Perioperative blood transfusion is associated with an increased risk for post-surgical infection following pancreaticoduodenectomy
HPB 2019cited by 41position: firstdoi
Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells
Oncotarget 2019cited by 16position: firstdoi
Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Molecular Cancer Therapeutics 2018cited by 118position: middledoi
Long-term Quality of Life and Gastrointestinal Functional Outcomes After Pancreaticoduodenectomy
Annals of Surgery 2018cited by 55position: middledoi
Tobacco Carcinogen–Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer
Cancer Research 2018cited by 44position: middledoi
Effects of Dietary Phosphate Restriction and Phosphate Binders on FGF23 Levels in CKD
Clinical Journal of the American Society of Nephrology 2013cited by 148position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Nipun B. Merchant · University of Miami16 papers (2018–2025)Nagaraj S. Nagathihalli · University of Miami14 papers (2018–2025)Siddharth Mehra · University of Miami9 papers (2020–2025)Samara P. Singh · Sylvester Comprehensive Cancer Center8 papers (2021–2025)Supriya Srinivasan · University of Miami8 papers (2018–2025)Xizi Dai · Cancer Research Center7 papers (2019–2022)Iago De Castro Silva · University of Miami7 papers (2021–2025)Yuguang Ban · University of Miami7 papers (2018–2025)Jashodeep Datta · University of Miami6 papers (2021–2024)Michael N. VanSaun · University of Miami6 papers (2018–2025)Vanessa T. Garrido · University of Miami6 papers (2020–2025)Zhiqun Zhou · University of Miami5 papers (2022–2025)Jason Castellanos · Amgen (United States)4 papers (2018–2021)Tulasigeri M. Totiger · University of Miami4 papers (2018–2025)Purushottam Lamichhane · Cancer Research Center4 papers (2018–2023)Nilesh Kashikar · Cone Health3 papers (2018–2020)Anna Bianchi · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia3 papers (2021–2022)Brent A. Willobee · University of Miami3 papers (2020–2021)Alexander A. Gaidarski · Baylor University Medical Center3 papers (2018–2021)Chanjuan Shi · Duke University Health System3 papers (2018–2022)